ClinicalTrials.gg
WithdrawnNCT02484768Updated Jun 30, 2015

IV Iron Treatment of Restless Legs Syndrome

A Phase 2 interventional study of Iron isomaltoside 1000 and Sodium Chloride 0.9% in Restless Legs Syndrome, sponsored by Pharmacosmos A/S. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-30.

Sponsored by Pharmacosmos A/S · Phase 2, Interventional, and Treatment

Why this study was withdrawn
as per GCP sponsor/company decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to to establish proof-of-concept for efficacy of iron isomaltoside 1000 in subjects with Restless Legs Syndrome.

The study is a randomised, comparative, double-blind study with a 3 months extension. Subjects with restless leg syndrome (RLS) will be randomised 2:1 to one of the following treat-ment groups:

  • Group A (42 subjects): 1000 mg iron isomaltoside 1000
  • Group B (21 subjects): Placebo infusion

Furthermore, non-responders, who continue to meet entry requirements, will receive 1000 mg iron isomaltoside 1000 at week 6.

Read the detailed description

RLS is a disorder of sensation with a prevalence of around 2-5 % of the population. RLS is extremely responsive to dopaminergic agents, but a second issue is that iron deficiency states may precipitate RLS in as much as 25-30 % of subjects with iron deficiency. RLS appears to be related to deficits in brain iron content and metabolism. Magnetic resonance imaging (MRI) images demonstrate a decrease in substantia nigra and red nucleus iron content. The severity of this decrease in brain iron content is correlated with the severity of symptoms. A number of patients are quite resistant to dietary iron repletion but do resolve symptoms with high doses of intravenous (IV) iron.

For the individual subject, there will be 4 phases to the study which includes teleconferences (TCs) and 2 visits.

The treatment and treatment evaluation is the main study.

02

Conditions studied

  • Restless Legs Syndrome
03

In context

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Lead sponsor

Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Diagnosis of RLS based upon the CH-RLSq and HTDI
  3. IRLS score ≥ 15 at baseline evaluation when off RLS medications
  4. Willingness to participate and signing the form

Exclusion criteria

Exclusion Criteria:

  1. S-ferritin > 300 ng/mL and/or TfS > 50 %
  2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemo-siderosis)
  3. Known to IV iron or any in the drug prod-ucts
  4. Pregnant or nursing women. In order to avoid pregnancy, women of childbearing po-tential have to use adequate (e.g. intrauterine devices, hormonal contra-ceptives, or double barrier method) during the whole study period and 7 days after the last dosing
  5. History of active asthma within the last 5 years
  6. Decompensated liver cirrhosis or active hepatitis (defined as ASAT or ALAT > 3 times )
  7. Active acute or chronic infections (assessed by clinical judgement supplied with WBC and CRP)
  8. Rheumatoid arthritis with symptoms or signs of active inflammation
  9. Pregnant or nursing women
  10. Previous IV iron treatment for RLS
  11. IV iron treatment within 1 year prior to screening
  12. Blood transfusion within 4 weeks prior to screening
  13. Planned elective surgery during the study
  14. Participation in any other interventional study where the study drug has not passed 5 half-lives prior to the screening
  15. Any other medical condition that, in the opinion of the Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study, e.g. history of multiple allergies, a , uncon-trolled hypertension, unstable ischaemic heart disease, or uncontrolled diabetes melli-tus
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group A

    Infusion of 1000 mg iron isomaltoside 1000 at baseline. The infusion is diluted in 100 mL 0.9 % sodium chloride and given over approximately 15 min

    Drug: Iron isomaltoside 1000

  • Placebo comparator
    Group B

    Infusion of 100 mL 0.9 % sodium chloride at baseline given over approximately 15 min

    Drug: Sodium Chloride 0.9%

Interventions

  • Intravenous treatment

    Also known as: Monofer

  • DrugSodium Chloride 0.9%

    Intravenous treatment

06

What researchers measure

Primary outcomes

  1. To measure the change in RLS symptoms from baseline to week 6 measured by the clinical global impression (CGI) score

    Time frame: 6 weeks

Secondary outcomes

  1. Change in RLS symptoms from baseline to week 4 and month 2 and 3 measured by the CGI score

    Time frame: 3 months

  2. Change in RLS symptoms from baseline to week 4 and 6 and month 2 and 3 measured by the International Restless Legs Scale (IRLS)

    Time frame: from baseline to t = 12 weeks

  3. Time from baseline to start of RLS medication

    Time frame: from baseline to t = 6 weeks

  4. Time from baseline to start of RLS medication or non-response (CGI ≥ 3 at week 6)

    Time frame: from baseline to t = 6 weeks

Other outcomes

  1. Type and incidence of adverse drug reactions (ADRs)

    Time frame: from baseline to t = 18 weeks

  2. Number of adverse events (AEs) of special interest

    (i.e. hypersensitivity symptoms such as: urticaria, oedema, bronchospasm, hypotension, cardiorespiratory arrest, syn-cope, unresponsiveness, or loss of consciousness at pre-specified time points in relation to administration of study drug)

    Time frame: from baseline to t = 18 weeks

  3. Change in haematology parameters, s-sodium, s-potassium, s-calcium, s-phosphate, s-urea, s-creatinine, s-albumin, s-bilirubin, aspartate aminotransferase (ASAT), and ala-nine aminotransferase (ALAT) from baseline to week 6 and month 3

    Time frame: from baseline to t = 18 weeks

  4. Change in vital signs (heart rate and blood pressure) during drug administration

    Time frame: from baseline to t = 18 weeks

  5. Clinical significant electrocardiogram (ECG) during drug administration

    Time frame: from baseline to t = 18 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2015
First posted
Jun 30, 2015
Start
Jan 2015
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Jun 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02484768
Lead sponsor
Pharmacosmos A/S
Collaborators
BioStata, Laboratory Corporation of America
Responsible party
Sponsor
First posted
Jun 30, 2015
Start date
Jan 2015
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Jun 30, 2015

Study contacts

Richard Allen, Assoc Prof
principal investigator · Johns Hopkins University Asthma& Allergy Bldg 1B76b 5501 Hopkins Bayview Blvd Baltimore, MD 21224 USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion